Latest Articles
Women waiting too long for NHS care because of ‘medical misogyny’, top doctor warns - AOL.com
Women waiting too long for NHS care because of ‘medical misogyny’, top doctor warns AOL.com
Published: April 14, 2026, 2:03 p.m.
HER2 ADC Shows Promise in Recurrent Endometrial Cancer - Medscape
HER2 ADC Shows Promise in Recurrent Endometrial Cancer Medscape
Published: April 14, 2026, 11:41 a.m.
Novel insights into the role of Annexin A2 signaling pathway in female reproductive system diseases: from mechanisms to advanced therapies.
Annexin A2 (ANXA2) is a calcium-dependent protein with high affinity for phospholipids, and its multifunctional nature has drawn increasing attention in the onset and progression of various disorders of the …
Published: April 14, 2026, midnight
Maine braces for another tick season amid promising Lyme vaccine trials - newscentermaine.com
Maine braces for another tick season amid promising Lyme vaccine trials newscentermaine.com
Published: April 13, 2026, 12:16 p.m.
GSK ovarian and womb cancer drug shows promise in early trial - FemTech World
GSK ovarian and womb cancer drug shows promise in early trial FemTech World
Published: April 13, 2026, 11:05 a.m.
Misdiagnosis, stigma, silence. Maha Gorton’s Her Health Majlis is breaking all three in women’s healthcare - Fast Company Middle East
Misdiagnosis, stigma, silence. Maha Gorton’s Her Health Majlis is breaking all three in women’s healthcare Fast Company Middle East
Published: April 13, 2026, 6:01 a.m.
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.
Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …
Published: April 13, 2026, midnight
GSK reports promising early results in ovarian and womb cancer drug trial - The Guardian
GSK reports promising early results in ovarian and womb cancer drug trial The Guardian
Published: April 12, 2026, 10:52 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KELO-AM
GSK sees blockbuster potential in targeted cancer therapy after promising early data KELO-AM
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KFGO
GSK sees blockbuster potential in targeted cancer therapy after promising early data KFGO
Published: April 12, 2026, 8:44 p.m.
Link copied to clipboard!